JP2004501153A5 - - Google Patents

Download PDF

Info

Publication number
JP2004501153A5
JP2004501153A5 JP2002504258A JP2002504258A JP2004501153A5 JP 2004501153 A5 JP2004501153 A5 JP 2004501153A5 JP 2002504258 A JP2002504258 A JP 2002504258A JP 2002504258 A JP2002504258 A JP 2002504258A JP 2004501153 A5 JP2004501153 A5 JP 2004501153A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutical composition
chlorophenyl
pharmaceutically acceptable
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002504258A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004501153A (ja
JP4919575B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2001/006747 external-priority patent/WO2001098302A1/en
Publication of JP2004501153A publication Critical patent/JP2004501153A/ja
Publication of JP2004501153A5 publication Critical patent/JP2004501153A5/ja
Application granted granted Critical
Publication of JP4919575B2 publication Critical patent/JP4919575B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2002504258A 2000-06-22 2001-06-13 ファルネシルトランスフェラーゼ阻害性1,2−環付加キノリン鏡像異性体 Expired - Lifetime JP4919575B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00202181 2000-06-22
EP00202181.4 2000-06-22
PCT/EP2001/006747 WO2001098302A1 (en) 2000-06-22 2001-06-13 Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer

Publications (3)

Publication Number Publication Date
JP2004501153A JP2004501153A (ja) 2004-01-15
JP2004501153A5 true JP2004501153A5 (enExample) 2008-07-17
JP4919575B2 JP4919575B2 (ja) 2012-04-18

Family

ID=8171675

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002504258A Expired - Lifetime JP4919575B2 (ja) 2000-06-22 2001-06-13 ファルネシルトランスフェラーゼ阻害性1,2−環付加キノリン鏡像異性体

Country Status (33)

Country Link
US (3) US20030114471A1 (enExample)
EP (1) EP1296984B1 (enExample)
JP (1) JP4919575B2 (enExample)
KR (2) KR100831940B1 (enExample)
CN (1) CN1207296C (enExample)
AR (1) AR030704A1 (enExample)
AT (1) ATE294804T1 (enExample)
AU (3) AU2001263962B2 (enExample)
BG (1) BG65894B1 (enExample)
BR (1) BRPI0111743B8 (enExample)
CA (1) CA2410232C (enExample)
CZ (1) CZ295278B6 (enExample)
DE (1) DE60110592T2 (enExample)
EA (1) EA005065B1 (enExample)
EE (1) EE04966B1 (enExample)
EG (1) EG24180A (enExample)
ES (1) ES2241830T3 (enExample)
HR (1) HRP20020989B1 (enExample)
HU (1) HU229095B1 (enExample)
IL (2) IL153560A0 (enExample)
IS (1) IS2596B (enExample)
JO (1) JO2361B1 (enExample)
MX (1) MXPA02012845A (enExample)
MY (1) MY127734A (enExample)
NO (1) NO324494B1 (enExample)
NZ (1) NZ522481A (enExample)
PA (1) PA8519501A1 (enExample)
PL (1) PL209521B1 (enExample)
SA (1) SA01220349B1 (enExample)
SK (1) SK285699B6 (enExample)
UA (1) UA73572C2 (enExample)
WO (1) WO2001098302A1 (enExample)
ZA (1) ZA200210305B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018135A1 (en) 2001-08-24 2003-03-06 Wyeth Holdings Corporation Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase
CA2481480C (en) 2002-04-15 2011-04-12 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
US20050003422A1 (en) 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
JP2017536403A (ja) * 2014-12-04 2017-12-07 アイガー・バイオファーマシューティカルズ・インコーポレイテッドEiger Biopharmaceuticals, Inc. デルタ肝炎ウイルス感染の治療
HUE054068T2 (hu) 2015-04-21 2021-08-30 Eiger Biopharmaceuticals Inc Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények
US10471055B2 (en) 2015-08-17 2019-11-12 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
HRP20210544T1 (hr) 2016-11-03 2021-08-20 Kura Oncology, Inc. Inhibitori farneziltransferaze za uporabu u liječenju raka

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1519765A (en) * 1974-09-05 1978-08-02 Ici Ltd Pesticidal dihydrotetrazolo(1,5a) quinazolines compositions and processes
US4141979A (en) * 1976-12-23 1979-02-27 Pfizer Inc. Tetrazolo[a]quinazol-5-ones antiallergy and antiulcer agents
GB9513577D0 (en) * 1995-07-04 1995-09-06 Brotherwood Rodney J Improvements in passenger carrying vehicles
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
DE69635966T2 (de) * 1995-12-08 2006-11-30 Janssen Pharmaceutica N.V. (Imidazol-5-yl)Methyl-2-Chinolinonderivate als Farnesyl Protein transferase Inhibitoren
CA2249615A1 (en) 1996-04-03 1997-10-09 Robert Gomez Inhibitors of farnesyl-protein transferase
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
SK146199A3 (en) * 1997-04-25 2000-06-12 Janssen Pharmaceutica Nv Farnesyltransferase inhibiting quinazolinones
IL133212A (en) 1997-06-02 2005-12-18 Janssen Pharmaceutica Nv History of use (imidazolil-5-yl) methyl-2-quinolinone that act as culture inhibitors of smooth muscle cells
HRP20000904A2 (en) 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
ID26987A (id) * 1998-07-06 2001-02-22 Janssen Pharmaceutica Nv Inhibitor-inhibitor transferase protein farnesil dengan sifat-sifat peka terhadap sinar radiasi in vivo
CA2341739C (en) * 1998-08-27 2005-07-12 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
KR20010072991A (ko) * 1998-08-27 2001-07-31 실버스타인 아써 에이. 항암제로서 유용한 알키닐-치환된 퀴놀린-2-온 유도체
PT1140935E (pt) * 1998-12-23 2003-10-31 Janssen Pharmaceutica Nv Derivados da quinolina 1,2-ciclizada
US6462201B1 (en) * 1998-12-29 2002-10-08 Isp Investments Inc. Process for the production of N-vinyl-2-pyrrolidone by vinylation
TR200201296T2 (tr) * 1999-02-11 2002-07-22 Pfizer Products Inc. Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
JP2003523381A (ja) 2000-02-24 2003-08-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 投与レジメン
JP4974439B2 (ja) 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する6−ヘテロシクリルメチルキノリノン誘導体
ATE409189T1 (de) 2000-09-25 2008-10-15 Janssen Pharmaceutica Nv Farnesyl transferase-hemmende 6- heterocyclylmethyl-chinolin und chinazol-derivate

Similar Documents

Publication Publication Date Title
EP3284467B1 (en) Nicotine-containing pharmaceutical compositions
RU2001134300A (ru) Фармацевтические и пищевые композиции, содержащие незаменимые жирные кислоты и гомоцистеин-понижающие агенты
JP2024063143A5 (enExample)
JPS62215527A (ja) アルツハイマー病治療薬
SI2529622T1 (en) Inhibitors of bruton's tyrosine kinase
JP2004505052A5 (enExample)
JPS5925323A (ja) プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
JP2005515966A5 (enExample)
AU2014277506A1 (en) Bisulfate of Janus kinase (JAK) inhibitor and preparation method therefor
PT1311272E (pt) Novos métodos utilizando inibidores de colinesterase
JP2019528302A5 (enExample)
WO2013002365A1 (ja) 止痒剤
TW202140022A (zh) 以prmt5抑制劑治療乾癬及其他自體免疫性病況之方法
AU2003227304B2 (en) Pharmaceutical formulation comprising melatonin
US20100292280A1 (en) Anti-pyretic vasodilators
JP2017533956A (ja) 筋肉痛を含む病態の治療のための組合せ
RU2018130097A (ru) Лечение экземы кистей
TWI411435B (zh) 4-環丙基甲氧基-n-(3,5-二氯-1-氧離子基吡啶-4-基)-5-(甲氧基)吡啶-2-甲醯胺於治療脊髓創傷之用途
JP2002515439A5 (enExample)
TWI439269B (zh) 4-環丙基甲氧基-n-(3,5-二氯-1-氧離子基吡啶-4-基)-5-(甲氧基)吡啶-2-甲醯胺於製備用於治療與帕金森氏病有關之運動障礙症的藥物之用途
JP2005513105A5 (enExample)
CN102552210B (zh) 一种恩替卡韦胶囊组合物及其制备方法
TWI423800B (zh) 4-環丙基甲氧基-n-(3,5-二氯-1-氧離子基吡啶-4-基)-5-(甲氧基)吡啶-2-甲醯胺於製備用於治療顱部創傷的藥物之用途
JP2003513888A (ja) 神経疾患治療用医薬品
US11478463B2 (en) Mast cell stabilizers for treatment of chronic inflammatory conditions